Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee --

-- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting --

BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented real-world evidence from its Innovations in Genicular Outcomes Registry, (IGOR), a first-of-its-kind multicenter, prospective, longitudinal observational registry. The first study demonstrated that EXPAREL® (bupivacaine liposome injectable suspension) was associated with improvements in pain, opioid use, function, and length of stay after receiving EXPAREL following total knee arthroplasty (TKA) as compared to patients who received conventional bupivacaine and ropivacaine. The second study demonstrated that cryoneurolysis treatment with ioveraº was associated with longer-term improvement in pain and function for up to 12 months, relative to a typical improvement of outcomes for 4-6 months following alternative intra-articular agents. The data were presented at the American Academy of Orthopedic Surgeons (AAOS) 2026 Annual Meeting taking place March 2-6 in New Orleans, Louisiana.

“OA is a unique condition that patients live with for decades and receive a myriad of pain treatments as their disease progresses. The IGOR is providing much-needed real-world evidence and in-depth insights into the patient journey, including the relationship between pain, opioid use, and recovery outcomes,” said Jonathan Slonin, Chief Medical Officer at Pacira. “The data being generated from this first-of-its-kind registry have the potential to meaningfully inform evidence-based preoperative pain management strategies and optimize postoperative recovery outcomes for patients with OA knee pain.”

Pacira Presentations at AAOS 2026:

1. “Intraoperative Liposomal Bupivacaine Is Associated With Improved Pain, Opioid Use, Functional, and Length of Stay Outcomes After Total Knee Arthroplasty: Real-world Evidence” (Poster #e0234): Evaluates the real-world effectiveness of liposomal bupivacaine (LB) versus conventional local anesthetics (LAs) in patients undergoing primary total knee arthroplasty (TKA). Data was collected from IGOR for opioid-naive patients who underwent unilateral primary TKA with up to 3 months of follow-up after surgery (LB, n=42; conventional LAs, n=183). The numerical rating scale (NRS) was used to assess acute pain during the first postsurgical week, and the Brief Pain Inventory-Short Form (BPI-SF) was used to assess chronic pain for subsequent time points. The data showed that patients receiving LB demonstrated lower average and worst pain scores (as measured by NRS) than those receiving conventional LAs in the first 5 days (average pain, 3.9 vs 4.9 [P